Research that helps control errors in gene expression as a safer and more effective alternative to conventional drugs has won from Prof. Hermona Soreq, Dean of the Hebrew University Science Faculty one of this year's Kaye Innovation awards.
Nava Swersky Sofer aims to turn the academic wisdom of Hebrew University researchers the into money. This year revenues reached $50 million, and the future looks promising.
A material designed to prevent adhesions following surgery, patented by Yissum, has won for Hebrew University Prof. Daniel Cohn of the Casali Instititue of Applied Chemistry first prize in this year's Kaye Awards for Innovation. The awards were presented during the recent 71st meeting of the Hebrew University Board of Governors.
Morria Biopharmaceuticals Plc, a biopharmaceutical company focused on the development of novel anti-inflammatory drugs, today announced that it has obtained regulatory approval from the South African Medicines Control Council (MCC) to initiate a Phase II study of MRX-4 in 105 patients suffering from allergic rhinitis (AR).
A novel device that enhances the diagnostic value of saliva has been produced by Hebrew University researchers. The disposable device clears whole saliva from its major protein constituent - alpha-amylase - to enable the detection of various low-abundance biomarkers.
Two researchers at Hebrew University of Jerusalem have designed synthetic molecules that may have future implications for the development of a new family of anti-cancer drugs.
Yissum, the technology transfer company of the Hebrew University of Jerusalem, introduced a novel device that enhances the diagnostic value of saliva.
Dr. Arie Dagan and Prof. Shimon Gatt have developed molecules that kill cancers without affecting normal tissue. The technology is patented and commercialized by Yissum, the Technology Transfer Company of the Hebrew University.
Où Va Le Biopartnering Franco-Israélien ?
A point of view on Israel's Biotech industry by Start Up Magazine
An Israeli professor has developed a new saliva-based disposable device that could be used to increase the diagnostic value of saliva, enabling physicians to do away with blood and other invasive diagnostic tests.
Yissum's technologies presented at Biomed 2008: An Assay and Kit and Device for Removing Amylase from Body Fluids and A Novel Anti-Inflammatory Agent
Economist: HUJI researcher Boris Rubinsky and his colleagues at Berkeley think they could help make medical imagining simpler, cheaper and more widely available. His team report in a recent issue of Public Library of Science (PloS) ONE on a design to use mobile phones to send raw imaging data to a base where it could be processed with the sophisticated software needed to create a medical image. The image could then be returned to the mobile phone and viewed on it. The mobile phone may join the stethoscope and the thermometer as an indispensable piece of medical kit.
Israeli Technology Transfer companies have become a role model for foreign academic institutes.
In 2006 researchers from the Hebrew University in Israel isolated a variant of the virus that causes Newcastle disease, a highly contagious disease in birds that can kill. This variant was able to target selectively cancer cells in humans. Trials on a form of aggressive primary brain tumour have shown one complete regression out of 14 treated patients.
Sophisticated medical images such as MRI and ultrasound scans and x-rays can be sent via cellular phones using a process developed at the Hebrew University of Jerusalem. The new technology, jointly owned by Yissum and the University of California is expected to be a boon not only for patients in developed counties, including rural areas with reduced access to medical services, but especially for those in the Third World.
Hybridization of biological and electric systems can serve as the basis for diverse applications ranging from biosensors and drug screening systems to neuro-electronic computers. Our technology enables the hybridization by creating an innovative physical linkage between cells and surface substrates, and using ion-sensitive field- effect transistors (ISFET) to transform the biological activity into readable electronic signals